For example, a phase II study in colorectal cancer patients of anti-CD47 IgG4 mAb Hu5F9-G4 in combination with Cetuximab, reported stable disease in 45% of patients, as well as increased macrophage tumour infiltration [108]. The gene discussed is CD47; the disease is neoplasm.